Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
TrkB is a tyrosine kinase receptor that is activated upon binding to brain-derived neurotrophic factor (BDNF). To date, the search for low-molecular-weight molecules mimicking BDNF’s action has been unsuccessful. Several molecules exerting antidepressive effects in vivo, such as 7,8-DHF, have been suggested to be TrkB agonists. However, more recent publications question this hypothesis. In this study, we developed a set of experimental procedures including the evaluation of direct interactions, dimerization, downstream signaling, and cytoprotection in parallel with physicochemical and ADME methods to verify the pharmacology of 7,8-DHF and other potential reference compounds, and perform screening for novel TrkB agonists. 7,8 DHF bound to TrkB with Kd = 1.3 μM; however, we were not able to observe any other activity against the TrkB receptor in SN56 T48 and differentiated SH-SY5Y cell lines. Moreover, the pharmacokinetic and pharmacodynamic effects of 7,8-DHF at doses of 1 and 50 mg/kg were examined in mice after i.v and oral administration, respectively. The poor pharmacokinetic properties and lack of observed activation of TrkB-dependent signaling in the brain confirmed that 7,8-DHF is not a relevant tool for studying TrkB activation in vivo. The binding profile for 133 molecular targets revealed a significant lack of selectivity of 7,8-DHF, suggesting a distinct functional profile independent of interaction with TrkB. Additionally, a compound library was screened in search of novel low-molecular-weight orthosteric TrkB agonists; however, we were not able to identify reliable drug candidates. Our results suggest that published reference compounds including 7,8-DHF do not activate TrkB, consistent with canonical dogma, which indicates that the reported pharmacological activity of these compounds should be interpreted carefully in a broad functional context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many scaffolds suffer rapid clearance, metabolic instability, and uneven brain exposure [62,131,132].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several proposed low molecular weight TrkB agonists have raised reproducibility and target specificity concerns, and central exposure remains difficult to optimize across scaffolds [131,132].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394 · cited 1×
“At the cellular level, BDNF acts as a key regulator of neurite outgrowth, synaptic plasticity, and long-term potentiation in the central nervous system [1,2].”
BackgroundNeurotrophin-regulated signalling pathways
Reichardt, L. F. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1894 · Cited by 2,195 · cited 2×
“The binding affinity differs between these molecules, and BDNF and NT4 interact much stronger with TrkB than NT3 [31].”
BackgroundNeurotrophin regulation of neural circuit development and function
Park, H., & Poo, M.-M. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3379 · Cited by 2,060 · cited 1×
“At the cellular level, BDNF acts as a key regulator of neurite outgrowth, synaptic plasticity, and long-term potentiation in the central nervous system [1,2].”
BackgroundBDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y.-A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,494 · cited 1×
“BDNF has antiapoptotic and neurotrophic properties affecting the viability and physiological condition of neurons [3,4].”
BackgroundDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 2×
“These may include side effects such as insomnia, sleepiness, and weight gain [10], and limited efficacy in drug-resistant forms of the disease [11].”
BackgroundConsiderations for the use of SH-SY5Y neuroblastoma cells in neurobiology
Kovalevich, J., & Langford, D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-640-5_2 · Cited by 1,005 · cited 1×
“The SH-SY5Y cell line differentiated by retinoic acid (RA) is a widely used neuron-like model in neurobiological research [27].”
Colucci-D’Amato, L., Speranza, L., & Volpicelli, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207777 · Cited by 991 · cited 2×
“The cytoprotective effect of BDNF has been demonstrated in many in vitro and in vivo models [28].”
BackgroundBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 1×
“Furthermore, BDNF appears to be a key transducer in mediating the therapeutic effects of known antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and ketamine, by inducing changes in neuroplasticity [9].”
BackgroundThe GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934 · cited 1×
“The interaction of the GABAA receptor was clinically proved to produce anxiolytic and antidepressant effects via reversing deficits in monoamine transmission in GABAergic machinery [42].”
BackgroundPharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783 · cited 1×
“A1A receptors reduce excitatory transmission by the regulation of potassium homeostasis, which leads to the inhibition of glutamate secretion in neuronal cells, whereas the A2A receptor modulates the sensitivity of the dopamine D2 receptor, typically in striatal neurons, which affects motoric functions [44].”
BackgroundReducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748 · cited 2×
“Binding Study 7,8-DHF was analyzed for binding in a broad panel of molecular targets recommended by Bowes et al., 2012 [30].”
MethodA selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone
Jang, S.-W., Liu, X., Yepes, M., Shepherd, K. R., Miller, G. W., Liu, Y., Wilson, W. D., Xiao, G., Blanchi, B., Sun, Y. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913572107 · Cited by 686 · cited 7×
“7,8-DHF has been postulated as a TrkB agonist and used as reference molecule for research into the TrkB receptor and development of new agonists [12,13,34].”
BackgroundMethodInfluentialSSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · cited 2×
“These may include side effects such as insomnia, sleepiness, and weight gain [10], and limited efficacy in drug-resistant forms of the disease [11].”
BackgroundAntidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
BDNF function and intracellular signaling in neurons.
Numakawa, T., Suzuki, S., Kumamaru, E., Adachi, N., Richards, M., & Kunugi, H. (2010) · PubMed · doi:10.14670/hh-25.237 · Cited by 597 · cited 1×
“Consequently, three intracellular signaling pathways, relating to PLCγ1, MAPK, and PI3K kinases, may become activated [5].”
BackgroundHetman, M., Kanning, K., Cavanaugh, J. E., & Xia, Z. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22569 · Cited by 575 · cited 1×
“BDNF has antiapoptotic and neurotrophic properties affecting the viability and physiological condition of neurons [3,4].”
BackgroundSmall molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397 · cited 1×
“The inhibition of COX-2 with celecoxib, a well-known nonsteroidal anti-inflammatory drug, reversed the behavioral deficits produced by chronic unpredictable stress in rats, and demonstrated efficacy in clinical trials with depressive patients, which was correlated with anti-inflammatory action [43,45,46].”
BackgroundBrain-derived neurotrophic factor: role in depression and suicide
Dwivedi, Y. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5700 · Cited by 355 · cited 1×
“Moreover, reduced expression of the TrkB receptor in depressive patients with suicide risk and suicidal ideation has also been observed [8].”
BackgroundThe Role of BDNF in Depression on the Basis of Its Location in the Neural Circuitry
Yu, H., & Chen, Z.-Y. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.184 · Cited by 343 · cited 1×
“Clinical evidence shows that patients suffering from depression demonstrate decreased BDNF levels in the hippocampus [7].”
BackgroundAbbasi, S.-H., Hosseini, F., Modabbernia, A., Ashrafi, M., & Akhondzadeh, S. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.033 · Cited by 339 · cited 1×
“The inhibition of COX-2 with celecoxib, a well-known nonsteroidal anti-inflammatory drug, reversed the behavioral deficits produced by chronic unpredictable stress in rats, and demonstrated efficacy in clinical trials with depressive patients, which was correlated with anti-inflammatory action [43,45,46].”
BackgroundN -acetylserotonin activates TrkB receptor in a circadian rhythm
Jang, S.-W., Liu, X., Pradoldej, S., Tosini, G., Chang, Q., Iuvone, P. M., & Ye, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912531107 · Cited by 214 · cited 3×
“Furthermore, Jang et al. (2010) showed that TrkB dimerizes upon 7,8-DHF binding to the extracellular domain using the pull-down assay [12].”
MethodInfluentialSolubility and Dissolution Profile Assessment in Drug Discovery
Sugano, K., Okazaki, A., Sugimoto, S., Tavornvipas, S., Omura, A., & Mano, T. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.225 · Cited by 212 · cited 1×
“The kinetic solubility was determined by the shake-flask protocol [50,51].”
MethodLiu, X., Chan, C.-B., Jang, S.-W., Pradoldej, S., Huang, J., He, K., Phun, L. H., France, S., Xiao, G., Jia, Y., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101206p · Cited by 208 · cited 2×
“7,8-DHF has been postulated as a TrkB agonist and used as reference molecule for research into the TrkB receptor and development of new agonists [12,13,34].”
BackgroundThe expanding role of BDNF: a therapeutic target for Alzheimer's disease?
Fumagalli, F., Racagni, G., & Riva, M. A. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500337 · Cited by 173 · cited 1×
“The natural ligand BDNF and peptides generally do not cross the blood–brain barrier (BBB); therefore, their systemic administration is not feasible [32].”
BackgroundChen, C., Wang, Z., Zhang, Z., Liu, X., Kang, S. S., Zhang, Y., & Ye, K. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718683115 · Cited by 167 · cited 2×
“However, it should be noted that, in our study, 7,8-DHF reached a lower concentration in the BALB/c mice’s brains after oral administration than was observed in other studies and mouse strains [29,40].”
BackgroundChen, J., Chua, K., Chua, C. C., Yu, H., Pei, A., Chua, B. H. L., Hamdy, R. C., Xu, X., & Liu, C.-F. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.054 · Cited by 162
Liu, X., Obianyo, O., Chan, C. B., Huang, J., Xue, S., Yang, J. J., Zeng, F., Goodman, M., & Ye, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562561 · Cited by 113 · cited 1×
“Jang et al. (2010) and Liu et al. (2014) reported binding affinities of 7,8-DHF in the nanomolar range (15.4 and 12.1 nM, respectively); however, these differences in binding affinity appear to result from the application of different methods because the Kd values for BDNF determined by MST were…”
MethodInfluentialFredlund, L., Winiwarter, S., & Hilgendorf, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01059 · Cited by 111 · cited 1×
“Passive permeability was investigated in 24-well-plate format using differentiated Caco-2 cells (CacoReady 24 well, ReadyCell, Barcelona, Spain), according to a previously published protocol [52] with proprietary modifications and with restrictions described in the product manual.”
MethodDeoxygedunin, a Natural Product with Potent Neurotrophic Activity in Mice
Jang, S.-W., Liu, X., Chan, C. B., France, S. A., Sayeed, I., Tang, W., Lin, X., Xiao, G., Andero, R., Chang, Q., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011528 · Cited by 101 · cited 4×
“7,8-DHF was originally described in the literature as a bioavailable compound that can pass through the BBB and demonstrated a functional effect in a TrkB-dependent manner after acute (5 mg/kg in TrkB F616A knock-in mice) and 14-day treatment (exposed to C57BL/6 in drinking water) [39].”
BackgroundMethodInfluentialMultiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists
Boltaev, U., Meyer, Y., Tolibzoda, F., Jacques, T., Gassaway, M., Xu, Q., Wagner, F., Zhang, Y.-L., Palmer, M., Holson, E., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aal1670 · Cited by 94 · cited 3×
“However, the use of 7,8-DHF as a research tool to study TrkB agonism was questioned by other groups who were not able to confirm TrkB activation [25,26].”
BackgroundInfluentialA Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease
Todd, D., Gowers, I., Dowler, S. J., Wall, M. D., McAllister, G., Fischer, D. F., Dijkstra, S., Fratantoni, S. A., van de Bospoort, R., Veenman-Koepke, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087923 · Cited by 93
Han, X., Zhu, S., Wang, B., Chen, L., Li, R., Yao, W., & Qu, Z. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.10.018 · Cited by 86
Emili, M., Guidi, S., Uguagliati, B., Giacomini, A., Bartesaghi, R., & Stagni, F. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1810625 · Cited by 85 · cited 1×
“7,8-DHF has been postulated as a TrkB agonist and used as reference molecule for research into the TrkB receptor and development of new agonists [12,13,34].”
BackgroundLiu, X., Qi, Q., Xiao, G., Li, J., Luo, H. R., & Ye, K. (2013) · Pharmacology · doi:10.1159/000346920 · Cited by 76 · cited 4×
“However, it should be noted that, in our study, 7,8-DHF reached a lower concentration in the BALB/c mice’s brains after oral administration than was observed in other studies and mouse strains [29,40].”
BackgroundInfluentialPresgraves, S. P., Borwege, S., Millan, M. J., & Joyce, J. N. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.06.021 · Cited by 58 · cited 1×
“, (2004), with the following modifications [49].”
N -acetyl serotonin derivatives as potent neuroprotectants for retinas
Shen, J., Ghai, K., Sompol, P., Liu, X., Cao, X., Iuvone, P. M., & Ye, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119201109 · Cited by 51
The non‐peptidyl fungal metabolite L‐783,281 activates TRK neurotrophin receptors
Wilkie, N., Wingrove, P. B., Bilsland, J. G., Young, L., Harper, S. J., Hefti, F., Ellis, S., & Pollack, S. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00504.x · Cited by 49
Synthesis of 3-Indolyl-2,5-dihydroxybenzoquinones
Pirrung, M. C., Park, K., & Li, Z. (2001) · Organic Letters · doi:10.1021/ol006852l · Cited by 49
7,8-Dihydroxyflavone reverses the depressive symptoms in mouse chronic mild stress
Zhang, M.-W., Zhang, S.-F., Li, Z.-H., & Han, F. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.035 · Cited by 46
Sudarshan, K., Boda, A. K., Dogra, S., Bose, I., Yadav, P. N., & Aidhen, I. S. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.057 · Cited by 43
Amin, N., Xie, S., Tan, X., Chen, Y., Ren, Q., Botchway, B. O. A., Hu, S., Ma, Y., Hu, Z., & Fang, M. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109939 · Cited by 43
Antidepressant-like effect of celecoxib piroxicam in rat models of depression
Santiago, R. M., Barbiero, J. K., Martynhak, B. J., Boschen, S. L., da Silva, L. M., Werner, M. F. D. P., Cunha, C. D., Andreatini, R., Lima, M. M. S., & Vital, M. A. B. F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1159-5 · Cited by 42 · cited 1×
“The inhibition of COX-2 with celecoxib, a well-known nonsteroidal anti-inflammatory drug, reversed the behavioral deficits produced by chronic unpredictable stress in rats, and demonstrated efficacy in clinical trials with depressive patients, which was correlated with anti-inflammatory action [43,45,46].”
BackgroundExploratory analysis of kinetic solubility measurements of a small molecule library
Guha, R., Dexheimer, T. S., Kestranek, A., Jadhav, A., Chervenak, A., Ford, M. G., Simeonov, A. M., Roth, G. P., & Thomas, C. J. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.05.005 · Cited by 40 · cited 1×
“The kinetic solubility was determined by the shake-flask protocol [50,51].”
MethodThe receptor tyrosine kinase TrkB signals without dimerization at the plasma membrane
Zahavi, E. E., Steinberg, N., Altman, T., Chein, M., Joshi, Y., Gradus, T., & Perlson, E. (2018) · Science Signaling · doi:10.1126/scisignal.aao4006 · Cited by 39 · cited 2×
“Nevertheless, TrkB is also able to signal as a monomer, activating only the ERK1/2-dependent pathway [6].”
BackgroundГудашева, Т. А., Логвинов, И. О., Антипова, Т. А., & Середенин, С. Б. (2013) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672913040121 · Cited by 33
Atifi, M. E., Buggia-Prévot, V., Platet, N., Benabid, A., Berger, F. R., & Sgambato, V. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.002 · Cited by 33
Chang, H., Wang, Y.-H., Tung, C., Yeh, C., & Liu, Y. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.5.531 · Cited by 31
Liu, Y., Johe, K. K., Sun, J., Hao, X., Wang, Y., Bi, X., & Baudry, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.10.038 · Cited by 25
Arai, K., Sato, S., SHIMIZU, S., Nitta, K., & Yamamoto, Y. (1981) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.29.1510 · Cited by 22 · cited 1×
“48 g/mol) [47], and CPL503113 (MW = 323.”
Fukuda, M., Takatori, A., Nakamura, Y., Suganami, A., Hoshino, T., Tamura, Y., & Nakagawara, A. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.04.017 · Cited by 19
Gunerka, P., Gala, K., Banach, M., Dominowski, J., Hucz‐Kalitowska, J., Mulewski, K., Hajnal, Á., Mikus, E. G., Smuga, D. A., Zagozda, M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236159 · Cited by 9 · cited 1×
“Metabolic Stability First-phase metabolic stability was investigated in vitro using human (HLM) and mouse (MLM) liver microsomes (Gibco, Thermo Fisher Scientific) as described in Gunerka et al., 2020, with some modifications [53].”
MethodSelf-citation7,8-Dihydroxyflavone Protects PC12 Cells against MPP+-Induced Cytotoxicity by Heme Oxygenase-1
Song, Y., & Han, X. (2019) · International Journal of Sciences · doi:10.18483/ijsci.1932 · Cited by 2
Cited by
TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury
Wang, Y., Liang, J., Xu, B., Yang, J., Wu, Z., & Cheng, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122282 · Cited by 152
TrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions
Tessarollo, L., & Yanpallewar, S. U. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.847572 · Cited by 89
Róg, T., Girych, M., & Bunker, A. (2021) · Pharmaceuticals · doi:10.3390/ph14101062 · Cited by 70
Unlocking Alzheimer’s Disease: The Role of BDNF Signaling in Neuropathology and Treatment
Alqahtani, S. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Hemeda, L. R., Faheem, S. A., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08857-x · Cited by 59
“In addition, allosteric interaction with TrkB offers new opportunities, and a shift toward the crossed transmembrane domain of the TrkB receptor as a target for novel agonist pharmacophores should be considered in future development engaging the BDNF/TrkB signaling pathway (Pankiewicz et al., 2021).”
Neurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48
Metadata
- Authors
- Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., Smuga, D., Dominowski, J., Janusz, A., Górka, M., Abramski, K., Napiórkowska, A., Nowotny, M., Dubiel, K., Kalita, K., Wieczorek, M., Pieczykolan, J., & Matłoka, M.
- Affiliations
- Medical University of Warsaw (PL)
- Celon Pharma (Poland) (PL)
- Structural Biology Center, International Institute of Molecular and Cell Biology, 02-109 Warsaw, Poland
- International Institute of Molecular and Cell Biology (PL)
- Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL)
- Corresponding author
- Matłoka, Mikołaj
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2021-07-21
- Volume
- 14
- Issue
- 8
- Pages
- 704
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC8398766
- OpenAlex
- W3186036424
- Cited by
- 42
- References
- 54
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 5 · 2021: 2
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Narodowe Centrum Badań i Rozwoju (POIR.01.02.00-00-0020/17-00)
- Ministerstwo Nauki i Szkolnictwa Wyższego (Doktorat Wdrożeniowy 50//DW/2017/01/1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- TrkB receptor, brain-derived neurotrophic factor, orthosteric agonists, receptor activation, pharmacokinetics, pharmacodynamics, receptor dimerization, downstream signaling, compound library screening, target selectivity, receptor tyrosine kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.